Compare Redwire Corporation (RDW) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Tenet Healthcare Corporation — how do they compare? Redwire Corporation trades at $9.93 (market cap $2.56B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Tenet Healthcare Corporation is far larger — about 8.2× Redwire Corporation's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Tenet Healthcare Corporation for 15 Days on average.
| RDW | THC | |
|---|---|---|
Market Cap | $2.56B | $20.92B |
Volume | 14,037,053 | 455,764 |
Sector | Industrials | Health |
52-Week High | $25.90 | $280.77 |
52-Week Low | $5.06 | $161.37 |
Typical Hold Time | 18 Days | 15 Days |
Enterprise Value | $2.09B | $32.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $10.24, down 3.58% with bearish technical signals despite 80% analyst buy ratings. The company shows strong revenue growth (89.6% YoY in Q2 2026) but faces profitability challenges with negative net margins (-57.26%) and consecutive earnings misses. Recent Space Force contract wins and partnerships highlight growth potential in the expanding space infrastructure market, though cash flow remains negative from operations.
The stock presents a high-risk growth opportunity with significant upside to the $14.88 consensus target if execution improves, but persistent losses and dependence on SpaceX's Starship timeline create substantial volatility. Investors must weigh strong institutional support against fundamental weaknesses in a speculative sector.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
